The orally active ETAR antagonist, atrasentan (ABT-627, XinlayTM, Abbott) (Opgenorth et al. 1996), attenuated disease progression as well as reduced morbidity in patients with PCa-induced bone metastases (Lalich et al. 2007). The gene discussed is EDNRA; the disease is posterior cortical atrophy.